FDA approves bepirovirsen, a finite treatment for chronic hepatitis B
Hibsago, GSK's antisense drug, is given for a fixed 24 weeks with the aim of a functional cure. In phase 3 trials, about one in five eligible patients reached that goal.
Breakthroughs & Cures.
Therapies that change the outlook for a disease: gene therapies, cell therapies and first-of-their-kind results.